Sirtex Medical Europe

Sirtex Medical Limited is an Australian company with an approved cancer treatment supplied globally. Sirtex's main commercialised product is a targeted radioactive treatment for liver cancer called SIR-Spheres® Y-90 resin microspheres.

Over 86,000 doses of SIR-Spheres Y-90 resin microspheres have been supplied to treat liver cancer patients at over 1,160 medical centres in over 40 countries.

This product has PMA approval from the U.S. Food & Drug Administration (FDA), the European Union (CE Mark) and Australia's Therapeutic Goods Administration (TGA).

Sirtex has manufacturing capabilities in the U.S., Singapore and Germany.